Innovation breakthrough in the Alzheimer’s disease pharmaceutical industry

npj Drug Discovery. 2026 Open access

Read full text
Authors: Hua Cheng, Leyi Kang, Yulong Xu, Rudolph E. Tanzi, C. Zhang, C. C. Wang
DOI: 10.1038/s44386-026-00044-7
Cited by: 2
References: 6

Abstract

Alzheimer's disease (AD) drug development has undergone cycles, driven initially by amyloid-β-based hypotheses and later setbacks by clinical failures. Recent advances in biotechnology, improved understanding of AD pathogenesis, and unmet medical needs have revitalized the field. This new wave is exemplified by lecanemab, the first fully FDA-approved disease-modifying therapy in two decades. We review approved and clinical-stage AD therapeutics using data from Cortellis and the FDA.

Fields of Study & Subjects

Alzheimer's disease research and treatments Cholinesterase and Neurodegenerative Diseases Pharmacological Receptor Mechanisms and Effects

Publication details

Journal / source
npj Drug Discovery.
Publisher
Springer Science and Business Media LLC
Volume
3
Issue
1
Pages
9–9
Publication date
2 March 2026
Language
EN